Study:
Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin`s Lymphoma
Rationale:
Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells. It is not yet known if combination chemotherapy is more effective with or without
rituximab for non-Hodgkin`s lymphoma.
Purpose:
Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without rituximab in treating older patients who have non-Hodgkin`s lymphoma.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lymphoma |
Biological: rituximab
Drug: CHOP regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate |
Phase 3 |
Verified by
Eastern Cooperative Oncology Group
August, 2010
Sponsored by: Eastern Cooperative Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003150
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Thomas M. Habermann, MD., Study Chair
Vicki A. Morrison, MD., Study Chair
James K. Weick, MD., Study Chair